Effect of suvorexant in circadian rhythm of blood pressure in hypertensive patients with insomnia

Effect of suvorexant in circadian rhythm of blood pressure in hypertensive patients with insomnia - ESCAPE Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018063

Enrollment

Registered

2015-06-25

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

Hypertensive patients with insomnia are enrolled. The patients receive suvorexant (20 mg/day at night) for 4 weeks. If the patients are elderly, they receive suvorexant (15 mg/day at night) for 4 week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who had the levels of fasting triglyceride more than 150 mg/dl. 2.Age is 20 years old or more and gender is male or female. 3.Patinets who did not have sleeping pills. 4.Patients who gave their written informed consent to participate for the present study.

Exclusion criteria

Exclusion criteria: 1.Severe cardiac failure. 2.Severe liver dysfunction. 3.Severe renal dysfunction. 4.Pregnancy or lactation in women. 5.Patients with a history of allergy to any component of the study medications. 6.Ineligible patients according to the judgment by physician.

Design outcomes

Primary

Measure	Time frame
Circadian rhythm of blood pressure	—

Secondary

Measure	Time frame
Early-morning blood pressure Nocturnal blood pressure Office blood pressure Changes in biochemical parameters Adverse effects	—

Countries

Japan

Contacts

Public ContactShin-ichiro Miura

Fukuoka University Hospital Department of Cardiology

miuras@cis.fukuoka-u.ac.jp81-92-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026